trending Market Intelligence /marketintelligence/en/news-insights/trending/W7HVQMKctYikbzyXOEFjYA2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Smith & Nephew reportedly being targeted by Elliott, as CEO moves on

Street Talk Episode 68 - As many investors zig away from bank stocks, 2 vets in the space zag toward them

Street Talk Episode 66 - Community banks tap the debt markets while the getting is good

Street Talk Episode 67 - Veteran investor tabs Mick Mulvaney to help with latest financial stock-focused fund

Street Talk Episode 65 - Deferral practices trap US bank portfolios in purgatory


Smith & Nephew reportedly being targeted by Elliott, as CEO moves on

Smith & Nephew Inc. is reportedly being targeted by U.S. activist investor Elliott Management Corp., although any stake-building in the U.K.-based company has yet to breach the 3% mark at which point it has to be disclosed to the London Stock Exchange.

For years, takeover speculation has swirled around the maker of orthopedic knees and hips, which has been run by Olivier Bohuon since 2011. The CEO yesterday announced plans to leave the company by the end of 2018, sparking speculation as to who might take over the role.

Elliott is best known for its aggressive approach to recouping losses suffered as a result of Argentina's debt default in 2001. More recently, the U.S.-based activist fund built a 9% stake in Akzo Nobel, a Dutch chemicals and paint group, whose chairman Elliott attempted to remove via court procedures. A three-month truce between Elliott and Akzo was reached Aug. 16.

So-called activist funds in the U.S. are increasingly turning to European companies, stealthily building up shareholdings in a bid to enforce their view and drive valuations higher, often by shaking up management and company strategies.

Canaccord Genuity analyst Kyle Rose initiated coverage of Smith & Nephew with a "Buy" rating and a $42 price target, citing the strong foundation offered by its broad product portfolio. "Smith & Nephew is the only orthopedic player that has diversified its product portfolio to include a focus on wound care," Rose wrote in a note to clients.

The analyst pointed out that, while management has "steadfastly maintained" their intention to remain independent, any potential M&A or activist activity has the opportunity to support additional upside to Canaccord's valuation.

Elliott spokesperson Sarah Rajani declined to comment on the stake-building first reported by Bloomberg, when contacted by S&P Global Market Intelligence.

Smith & Nephew's peers in the orthopedics business include Stryker Corp. and Zimmer Biomet Holdings Inc.